I-Ocrevus (ocrelizumab) - Izifundo eziSebenzayo

Ocrevus (ocrelizumab) lichiza lebhayoloji elisetyenziselwa ukunyanga i-multiple sclerosis (MS) kunye ne-rheumatoid arthritis (RA). Ichiza lavunywa yi-FDA ngo-2017 kunyango lwe-MS kwaye ngo-2021 kunyango lwe-RA.

Isenzo se-Ocrevus sisekelwe ekuvaleni iprotheni ye-CD20, ekhoyo kumphezulu wezinye iiseli ze-immune system, kubandakanywa neeseli ezidlala indima ebalulekileyo ekuphuhliseni i-MS kunye ne-RA. Ukuthintela iprotheyini ye-CD20 kunokunciphisa ukusebenza kwamajoni omzimba kunye nokunciphisa ukudumba okukhokelela kumonakalo wezicubu.

Izifundo malunga nokusebenza kwe-Ocrevus kunyango lwe-MS kunye ne-RA ziye zaqhutywa iminyaka emininzi. Olunye lwezifundo zokuqala, olwapapashwa kwiLancet ngo-2017, lwabizwa ngokuba "Ukusebenza kunye nokhuseleko lwe-Ocrevus kwi-primary progressive multiple sclerosis." Uphononongo lwenziwe kwizigulane ezingaphezu kwama-700 ezifumene i-Ocrevus okanye i-placebo kwiiveki ezingama-96. Iziphumo zabonisa ukuba i-Ocrevus yanciphisa kakhulu ukuqhubeka kwe-MS xa kuthelekiswa ne-placebo.

Olunye uphononongo olupapashwe kwiNew England Journal of Medicine ngo-2017 luphande ukusebenza kwe-Ocrevus kwi-relapsing-remitting multiple sclerosis (RRMS). Uphononongo lwenziwe kwizigulane ezingaphezu kwe-1300 ezifumene i-Ocrevus okanye elinye iyeza lonyango lwe-RRMS. Iziphumo zibonise ukuba i-Ocrevus inciphise kakhulu inani lokuphinda libuyele kwizigulana xa kuthelekiswa nelinye iyeza.

Izifundo malunga nokusebenza kwe-Ocrevus kwi-RA nazo zenziwe. Enye yazo, epapashwe kwiLancet ngo-2019, yavavanya ukusebenza kwe-Ocrevus kwi-seropositive RA, yenye yezona zinto zinzima.